$6.22
1.89% today
Nasdaq, Nov 20, 10:16 pm CET
ISIN
US6700021040
Symbol
NVAX

Novavax, Inc. Stock price

$6.34
-2.45 27.87% 1M
-1.40 18.09% 6M
-1.70 21.14% YTD
-1.66 20.75% 1Y
-12.61 66.54% 3Y
-80.06 92.66% 5Y
-134.46 95.50% 10Y
-59.46 90.36% 20Y
Nasdaq, Closing price Wed, Nov 19 2025
-0.23 3.50%
ISIN
US6700021040
Symbol
NVAX
Industry

New AI Insights on Novavax, Inc. Insights AI Insights on Novavax, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?

Key metrics

Basic
Market capitalization
$1.0b
Enterprise Value
$646.4m
Net debt
positive
Cash
$612.3m
Shares outstanding
162.2m
Valuation (TTM | estimate)
P/E
2.7 | 2.7
P/S
1.0 | 0.9
EV/Sales
0.6 | 0.6
EV/FCF
negative
P/B
27.4
Financial Health
Equity Ratio
-40.0%
Return on Equity
30.1%
ROCE
38.7%
ROIC
84.0%
Debt/Equity
6.1
Financials (TTM | estimate)
Revenue
$1.1b | $1.1b
EBITDA
$407.5m | $466.5m
EBIT
$366.4m | $483.8m
Net Income
$422.8m | $377.3m
Free Cash Flow
$-635.7m
Growth (TTM | estimate)
Revenue
9.2% | 59.5%
EBITDA
269.2% | 354.3%
EBIT
228.0% | 308.6%
Net Income
243.6% | 301.2%
Free Cash Flow
-2,727.9%
Margin (TTM | estimate)
Gross
88.3%
EBITDA
37.8% | 42.9%
EBIT
34.0%
Net
39.2% | 34.7%
Free Cash Flow
-58.9%
More
EPS
$2.4
FCF per Share
$-3.9
Short interest
29.9%
Employees
952
Rev per Employee
$720.0k
Show more

Is Novavax, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Novavax, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Novavax, Inc. forecast:

10x Buy
67%
2x Hold
13%
3x Sell
20%

Analyst Opinions

15 Analysts have issued a Novavax, Inc. forecast:

Buy
67%
Hold
13%
Sell
20%

Financial data from Novavax, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,079 1,079
9% 9%
100%
- Direct Costs 126 126
65% 65%
12%
952 952
51% 51%
88%
- Selling and Administrative Expenses 228 228
49% 49%
21%
- Research and Development Expense 358 358
24% 24%
33%
408 408
269% 269%
38%
- Depreciation and Amortization 41 41
9% 9%
4%
EBIT (Operating Income) EBIT 366 366
228% 228%
34%
Net Profit 423 423
244% 244%
39%

In millions USD.

Don't miss a Thing! We will send you all news about Novavax, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novavax, Inc. Stock News

Neutral
Seeking Alpha
one day ago
Novavax, Inc. ( NVAX ) Jefferies London Healthcare Conference 2025 November 19, 2025 11:30 AM EST Company Participants Ruxandra Draghia-Akli - Executive VP and Head of Research & Development James Kelly - Executive VP, CFO & Treasurer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division Welcome to Jefferies London He...
Negative
Reuters
8 days ago
Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no progress is made in the next four months.
Neutral
PRNewsWire
8 days ago
GAITHERSBURG, Md. , Nov. 12, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conference: Jefferies London Healthcare Conference: Fireside Chat Date: Wednesday, November 19, 2025 Time: 4:30 p.m.
More Novavax, Inc. News

Company Profile

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Head office United States
CEO John Jacobs
Employees 952
Founded 1987
Website www.novavax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today